text:
what benefits does taking a data-driven approach to talent mining offer companies?
more hr tech articles.
why robotic process automation could be your key to success in high-volume hiring.
are you equipped to recruit in a virtual environment?
which HR tasks are best-suited to automation?
why employers look to HR tech to reduce bias in hiring.
what google for jobs means for your talent acquisition strategy.
The global talent pool has grown in recent years. According to the World Bank, the total workforce grew from 2.327 billion people in 1990 to 3.449 billion people in 2017. Nevertheless, many countries are still experiencing a talent scarcity — a fact that is currently a primary concern for business leaders worldwide. This talent scarcity is mainly caused by a skills shortage, as rapid technological advancements demand different and new abilities.
However, having the right talent remains critical to organizations' ability to meet their operational objectives. As such, taking a data-driven approach to talent mining offers significant benefits to talent leaders. Unfortunately, it also comes with some challenges. Here's what talent leaders need to know.
challenges to developing a data-driven approach
Both public and private organizations collect talent data and use it to try to predict talent shortages and consequently define solutions. However, even with the ready availability of big data and increasingly powerful talent analytics tools, developing a clear overview of the talent landscape, pinpointing talent scarcity, and determining effective solutions still proves challenging.
While collecting data is becoming increasingly easier, it's still not always possible to collect it in real-time. As a result, analytics are often based on historic data, which doesn't always provide an accurate picture of the current state, let alone provide a solid foundation to predict future states. At the same time, collecting data requires an investment of time and money, which isn't always available, depending on organizational priorities. Furthermore, due to rapid technological developments, it's impossible to know which skills will be in demand in the near and distant future. For example, advanced manufacturing is a relatively new field, and though it's already affected jobs somewhat, the majority of talent leaders believe it's only now starting to have a real impact on employee skills. Finally, quickly changing socioeconomic realities can make it more difficult to interpret data correctly. For example, people are looking for alternative work arrangements, more people are working past retirement age and emerging markets are seeing the growth of a larger middle class. All three of these trends have developed in a relatively short period of time — yet all three are important for organizations developing workforce plans to be aware of.
developing a data-driven approach
Despite these challenges, it is possible to develop an effective, data-driven approach to talent mining. This requires that talent leaders study industry benchmarks and best practices in regard to talent analytics; then overlay those on their own procedures to develop unique processes that work for their organizations.
In addition, they need to select strong analytics applications that enable them to source and analyze data from their internal markets, as well as external sources. For example, Crunchr is an application that not only offers robust talent analytics capabilities, but also predictive modeling capabilities to examine signals that indicate high performers are thinking of jumping ship.
Finally, organizations need to take multiple factors into account when mining data, such as rapidly changing technologies, talent mobility, in- and external talent pools, and talent availabilities in other geographies and industries.
the benefits of a data-driven approach
When implemented correctly, a data-driven approach to talent mining can offer several distinct benefits:
The organization gains visibility of its own internal talent market. It can see where current talent is located — whether that's in a different division or geography — and can determine whether that talent might be redeployed in more pressing roles. At the same time, it also gains an overview of high-potential employees who could be up-skilled to meet future talent needs.
A data-driven approach offers the ability to predict skills shortages. Analytics capabilities are expanding to be able to predict — to a certain extent — future skills needs. For example, when combined with AI, analytics can use aggregated data to predict which skills are in increasing demand and will consequently be in short supply. This enables organizations to prepare their talent strategies accordingly.
It can help organizations locate external talent pools. Utilizing external talent data from other industries and geographies allows companies to locate individuals with in-demand skills outside of their immediate location and industry.
It can provide the ability to use predictive modeling to better engage and retain the current workforce. For example, analytics can reveal that engagement is low, which would signal the need for the company to concentrate on improving employee engagement and satisfaction.
It should be clear that without the right approach, data alone cannot find talent or signal when a talent shortage is likely to occur. But with the right approach that takes all relevant factors into account, talent leaders who apply robust analytics to talent data can greatly enhance their organizations' view of the ever-evolving talent landscape — and as a result, improve their access to the talent their companies need.
If you want to know more about the HR trends driving change in 2018, request our annual trends report here.


BIO-LAND promotes biological and organic agriculture, the recovery of natural and traditional industrial practices, as well as the use of cleaner and ecological commercial procedures, respecting the health of human beings and their environment. All of these aim to contribute to a healthier and more supportive future world.
This conditioner is made with the freshest organic products. Comes in a 430ml plastic bottle.


text:
JavaScript founder Brendan Eich's company could face legal action
Q&A: JavaScript creator Brendan Eich puts Brave face on the Web.
Brave is the name, ad-blocking the game of new browser
Opera pulls trigger on baked-in ad blocker
'Privacy first' Brave browser exits beta
By blocking trackers, invasive ads, and device fingerprinting by default, the open source browser had drawn protest from content publishers
Brave Software has launched Brave 1.0, the official GA release of its controversial, privacy-focused web browser.
The open source browser combines a blockchain-based digital advertising and payments platform and "privacy by design," combatting "surveillance capitalism" by blocking trackers, invasive ads, and device fingerprinting. This improves speed, privacy, security, and performance, the company said.
[ Also on InfoWorld: 10 software development cults to join ]
Default settings also block malware, malvertising, and phishing. Also, embedded plugins, viewed as a security risk, are disabled by default. Browsing data stays private and never leaves the user's device, with Brave not seeing the data on its servers or selling data to third parties.
Specific features of the Brave browser include:
Brave Shields, which blocks third-party ads, trackers, and auto-play videos. It is on by default and can be customized.
Brave Ads that compensate users for their attention. A blockchain advertising model shares 70 percent of ad revenue with users via Basic Attention Tokens, or BAT. BAT can be earned out of a Brave Rewards wallet and converted to digital assets and fiat currencies. Online creators can be supported. Brave Rewards features a wallet for desktop and mobile users.
Brave Software was founded by JavaScript inventor Brendan Eich, who is now Brave CEO. In 2016 Brave drew the ire of content publishers, who objected to the company's plans to incorporate ad blocking in the browser. Brave today said the objections were over a model that was explored but never implemented; the model is now opt-in, with privacy-preserving ads delivered to a user's device via a notification.
The Brave browser is intended to provide a smooth transition for users switching from Chrome or another browser. Bookmarks, cookies, and passwords can be imported. The browser previously was in a beta release that had attracted 8.7 million monthly users.
Where to download Brave
The Brave browser is available for Windows, MacOS, Linux, Android, and iOS. You can download Brave from the company website, Google Play, or the Apple App Store.

redpajama_set_name: RedPajamaCommonCrawl


text:
Het Estadio Hernando Siles is een multifunctioneel stadion in La Paz, de hoofdstad van Bolivia. Het stadion wordt vooral gebruikt voor voetbalwedstrijden. De clubs Club Bolívar, The Strongest, Chaco Petrolero, Club Mariscal Braun, Fraternidad Tigres, Club 31 de Octubre en het Boliviaans voetbalelftal spelen in dit stadion hun thuiswedstrijden. In het stadion kunnen 41.000 toeschouwers. Het stadion is vernoemd naar Hernando Siles Reyes (1882–1942), een Boliviaanse politicus die van 1926 tot 1930 president was van het land.

Historie
Het stadion werd in 1963 gebruikt voor een groot internationaal voetbaltoernooi, de Copa América. In dit stadion waren 11 wedstrijden. Het toernooi bestond uit alleen een groepsfase waarin ieder land een keer tegen elkaar speelt. Het gastland Bolivia speelde in dit stadion onder andere tegen het elftal van Ecuador (4–4) en Peru (3–2). Dat land zou uiteindelijk ook de voor de eerste keer winnaar worden van de Copa América.

In 1997 werd de Copa América weer in Bolivia gehouden en ook nu werd dit stadion gebruikt om voetbalwedstrijden te spelen.. De drie groepswedstrijden van het gastland waren in dit stadion, de kwartfinale tussen Bolivia en Colombia (2–1), de halve finale tussen Bolivia en Mexico (3–1) en de finale op, 29 juni 1997, tussen Bolivia en Brazilië (1–3).

In 2007 mocht er van de FIFA enkele weken niet in dit stadion gespeeld worden. Als buitenlandse teams het in dit stadion op moesten nemen tegen het nationale voetbalelftal van Bolivia was er door de hoogte (het stadion ligt 3.637 meter boven zeeniveau) een oneerlijk voordeel voor de thuisploeg. Tegenstanders kregen onvoldoende tijd om te acclimatiseren alvorens ze de wedstrijd speelden. Later werd bekendgemaakt dat dit verbod niet meer geldt voor dit stadion.

Hernando Siles
Sport in La Paz

redpajama_set_name: RedPajamaWikipedia


Thin flexible clear plastic 12 inch ruler. 1/16th of an inch scale on one edge and a 30 cm metric scale on the other.
Clear 12 inch ruler made from thin, flexible plastic. The C-thru No. 36 ruler has a 1/16th of an inch scale on one edge and a 30 cm metric scale on the other. This clear ruler is 1 inch wide and 12 inches long.


text:
import wataru.workflow.utils as wfutils
import wataru.workflow.state as wfstate
import os
import sys

class CommandBase:
    def apply_arguments(self, parser):
        parser.add_argument('--config-path', action='store', dest='configpath', default='')

    def pre_execute(self, namespace):
        # prepare settings
        self.settings = wfutils.get_setttings_from_configpath(os.path.abspath(namespace.configpath))

        # setup PYTHONPATH
        if self.settings['general']['project_base_path'] not in sys.path:
            sys.path.append(self.settings['general']['project_base_path'])

        # setup db
        wfstate.setup(self.settings['db'])

    def execute(self, namespace):
        raise NotImplementedError()

    def execute_all(self, namespace):
        self.pre_execute(namespace)
        self.execute(namespace)

redpajama_set_name: RedPajamaGithub


text:
Immunotherapy in metastatic or recurrent cervical cancer
By Dr Dearbhaile Collins | July 3, 2019 | 0
Dr Dearbhaile Collins outlines the latest trial data on immunotherapies for cervical cancer
The National Cancer Registry Ireland records 262 new cases of invasive cervical cancer in Ireland each year. This is predominantly a disease of younger women, with over 47 per cent of patients under the age of 45 years old at diagnosis. Squamous cell carcinoma of the cervix is primarily the result of infection with the human papillomavirus (HPV). It is estimated that 75-80 per cent of women are infected by HPV during their lifetime, but most women successfully clear the virus with an appropriate immune response. However, in some, the virus evades the host immune system and can result in the development of chronic infection with the potential initiation of carcinoma.
Despite much research into cervical cancer, the current treatment for advanced and metastatic disease has not changed since the GOG204 trial established cisplatin with paclitaxel as first-line chemotherapy in 2009. The addition of bevacizumab, an anti-angiogenic agent, improved overall survival by almost four months in 2014 as part of the GOG240 trial and the trio of compounds are now considered international standard of care. Despite a multitude of other agents being trialled in this disease type, there has been no further substantial impact on patient outcome over the years.
Immune checkpoint inhibitors
More recently, the response of cervical cancer to immunotherapy agents in the form of immune checkpoint inhibitors (ICI) and vaccine treatments has been explored. The term 'immunotherapy' encompasses a variety of immune system modulating drugs that attempt to 'turn on' the patient's immune response to the cancer itself. Examples of ICI agents and their targets are found in Table 1. Immunotherapy can also be used to describe vaccine and T-cell directed therapies. Modifying the immune system with such compounds has been hypothesised to be more efficacious in virus-driven cancers such as the HPV-triggered cervical cancer. Additionally, up to 67 per cent of squamous cervical cancer express high levels of a potential biomarker of response to immunotherapy, the PD-L1 receptor.
Broadly speaking, current licensing and approval for immunotherapy in the form of ICIs in Ireland includes metastatic malignant melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, urothelial cancer after platinum-containing regimens, head and neck cancer, Hodgkin's lymphoma post-brentuximab vedotin and Merkel cell carcinoma. Some of these indications, although not all, rely on a pre-specified certain level of expression of the PD-L1 receptor. For example, pembrolizumab is the first-line treatment in preference to chemotherapy in NSCLC if PD-L1 expression of the tumour cells exceeds 50 per cent. However, while high tumour PD-L1 expression can result in greater tumour responses to ICI treatment, it is by no means guaranteed. Problems with PD-L1 interpretation, expression differences within the tumour itself (heterogeneity), representative biopsy sampling concerns, changes in receptor expression over time and location are all significant barriers to accurate PD-L1 assessment and thus predicting response to ICIs. Furthermore, some high PD-L1 expressers still fail to respond to ICI treatment and other patients with low expression have excellent, durable responses. It should also be noted that different cancer types have different 'cut-off' levels for PD-L1 expression and some refer to tumour expression only, whereas in cervical cancer the expression includes that on the tumour as well as the surrounding immune cells, what is known as the 'combined positive score' (CPS).
The first ICI tested in cervical cancer was ipilimumab; an antibody targeted against the cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) receptor. Lheureux et al published in JAMA Oncology in 2017 on 34 evaluable patients, with one single partial response (overall response rate (ORR) 3 per cent) and 10 patients with stable disease. Median progression-free survival (PFS) was only 2.5 months and overall survival (OS) was 8.5 months. Due to this low anti-tumour activity, ipilimumab is not being further studied as a single agent in cervical cancer.
A cohort of metastatic cervical cancer patients from the KEYNOTE-028 phase 1 basket study reported the efficacy of the single agent pembrolizumab with an ORR of 12.5 per cent and six-month PFS of 13 per cent in 24 patients studied. These results led to the larger phase 2 KEYNOTE-158 trial of pembrolizumab monotherapy (NCT02628067). In preliminary data presented at the 2017 Annual Society of Clinical Oncology (ASCO) meeting, among the first 82 patients enrolled in the advanced squamous cell cervical cancer cohort, the ORR was 12 per cent. Among 77 patients with PD-L1-positive cervical cancer, defined as PD-L1 CPS greater than or equal to 1 per cent, the ORR was 14.3 per cent. All patients had received more than one prior chemotherapy regimen in the metastatic setting. These results were updated one year later at ASCO 2018 with ORR of 14.6 per cent in the 82 PD-L1-positive patients studied. Based on these results, the US Food and Drug Administration (FDA) approved pembrolizumab for use in metastatic cervical cancer following failure of chemotherapy in those cancers overexpressing PD-L1 in at least 1 per cent of the sampled tumour or immune cells.
Other ICI agents are also being assessed. The multicohort phase 1/2 CheckMate 358 study explored nivolumab and nivolumab-based combination therapy in patients with virus-associated tumours, including a cohort of patients with recurrent or metastatic cervical, vaginal, and vulvar cancers. In 2017, at ASCO, they reported on the advanced cervical cancer cohort comprising only 19 patients and reported an ORR of 26.3 per cent regardless of PD-L1 status. There was a higher ORR in treatment-naïve patients at 28.6 per cent compared with 17.6 per cent in previously treated patients, but numbers in this study are small. The median PFS was only 5.5 months. In 2018, at the annual ASCO conference, Santin et al reported another phase 2 study of 26 metastatic or recurrent cervical cancer patients with nivolumab. In this trial, there was only one partial response (ORR 4 per cent) that lasted 3.8 months and 36 per cent of patients with stable disease with a median duration of stability of 5.7 months. More recently, nivolumab in combination with an IDO1 inhibitor, BMS-986205, described a 25 per cent ORR in 12 cervical cancer patients and the results of further study with this combination is awaited.
Cemiplimab recently reported its interim data from phase 1 cohorts of patients with metastatic cervical cancer. With 20 patients evaluable for tumour response, the ORR was 10 per cent comprising only two partial responses. This ICI is currently being assessed against chemotherapy in a randomised phase 3 study in metastatic or recurrent platinum-refractory cervical cancer (GOG 3016/ENGOT-cx9).
Vaccine therapies
In addition to ICI treatment, there has been parallel interest in vaccine therapy for the treatment of advanced cervical cancer. The existing preventative vaccines against HPV cannot eliminate pre-existing HPV infections. As well as prevention, they may also boost weak immune responses to the virus. ADXS11-001 is a biologically engineered, live-attenuated Listeria monocytogenes (LM) vaccine. These vectors are internalised by antigen-presenting cells and dendritic cells, and once inside they release in the cytosol a highly immunogenic fusion protein, which promotes the differentiation of cytotoxic T-lymphocytes that can recognise and infiltrate the tumour. A phase 3 trial for high-risk and advanced cervical cancer (AIM2CERV) is currently recruiting participants (NCT02853604).
GOG/NRG-0265 studied patients with metastatic or locally advanced HPV-related squamous cell cervical cancer (NCT01266460). Fifty patients were treated with three doses of ADXS11-001, 1 × 109 colony forming units, monthly. The ORR was 2 per cent with one complete response. Median OS was 6.2 months and 12-month survival was 38 per cent. An Indian phase 2 trial, involving 110 patients with recurrent or persistent cervical cancer randomised to receive three or four doses of ADXS11-001 with cisplatin-based chemotherapy, showed an ORR of 11 per cent. VGX-3100 is a DNA vaccine being tested in a phase 1/2a trial in women with new, recurrent or persistent cervical cancer (NCT02172911).
Most vaccines in development are focusing efforts to induce regression of in situ or early stage cervical cancer before it becomes invasive, such as cervical intraepithelial neoplasia (CIN) 2 and 3. Multiple vaccines are being tested in this space including (1) oral L. casei bacterial vector vaccine GLBL101c, expressing a modified HPV-16 E7, (2) a MVA vector-TG4001 based on HPV-16 E6/7 and IL-2, and (3) the DNA vaccine GX-188E co-expresses the HPV-16 and -18 antigens E6 and E7, and the FMS-like tyrosine kinase-3 ligand, and (4) VGX-3100 noted above and many other vaccines at varying stages of development.
Adoptive cell transfer and chimeric antigen receptor (CAR) T-cell therapies are also being explored in advanced cervical cancer although data with these genetically modified immune cell treatments is very preliminary and at an early stage of development. No cervical cancer clinical trial results have been published to-date with these novel strategies.
Where we are now?
Overall, the modest results with ICI and vaccine therapy in squamous cell advanced and metastatic cervical cancer need to be considered carefully. On one hand, the response rates have been on the whole disappointing. If we compare pembrolizumab response rates from cervical cancer to other cancers, such as NSCLC, bladder cancer, and malignant melanoma, ORR in similar post-chemotherapy, advanced and metastatic patient groups were 18 per cent, 21 per cent, and 38 per cent respectively. On the other hand, little improvement of any type has been made in the field of cervical cancer over the years, so any agent with activity fuels promise and potential. Additionally, unlike with other historic treatments such as chemotherapy, there can be durable and lasting responses with ICI agents in the small numbers of patients where it is effective.
The future clinical focus in cervical cancer immunotherapy studies will be in combination with other agents; for example, chemotherapy, other immunomodulatory agents and targeted therapies as well as moving these compounds earlier in the disease trajectory, such as with definitive radiotherapy. Hopefully, these strategies will increase tumour response rates, enhance patient survival and overall outcome, although it will take up to five years before we know whether these approaches are successful.
Posted in Clinical News, ISMO Related


Comments - Interesting portrait of an oni or demon dressed as a priest, one of the standard Otsu-e characters. Otsu-e were traditional folk paintings sold to travelers during the Edo era in Otsu on Lake Biwa near Kyoto. They featured easily recognizable figures, such as the standard bearer, the Wisteria Maiden, an oni, and the samurai Benkei carrying a temple bell. A charming reprint of this classic Otsu-e figure.
Image Size - 16" x 10 1/4"


Before Ravelry even existed, designer Anna Dalvi was running mystery knitalongs (KALs) for her gorgeous lace shawls on Yahoo groups. Dalvi's skill at translating natural and mythical inspirations into stunning lace creations drew more than 7,000 knitters to her KALs.
Now, she has gathered all 14 of her wildly popular Mystic shawl designs into one book, stunningly photographed by Caro Sheridan. The book also includes photos of beautiful examples that other knitters created during the knitalongs, capturing the true community spirit of the KAL and the knitting world at large.
Mystic Shawls spans a wide variety of shapes and constructions, giving you rewarding knitting for years to come.
This book is available in both print and digital format. Please note that the digital format is listed separately. You will receive a PDF download of the book with your print purchase.
This is the first in the Mystic series at Cooperative Press. Mystic Shawls 2 was published by CP in 2017.


Tyler is well-loved by his friends and clients. He is a seasoned Redding realtor eager to help those looking for property in Redding, CA, Red Bluff, CA or Shasta Lake City, CA. He has access to all sorts of houses for sale and is ready to help.
You found us our Dream Home!!!
The home and property you helped us get is amazing. I wake up every morning and feel like the luckiest man alive here with my girls. I can never thank you enough for helping us find our dream home!!!


text:
package com.ilivoo.voom.model.test.packet;

import com.ilivoo.common.socket.serializing.message.Message;

public class SM_Session_Connect extends Message{

}


RAILROAD.NET • View topic - Blueliner?
Yes that is it! thanks for the information.
R36 Combine Coach wrote: 9130 to be correct.
Survey says you are right. 9135.
It's also landlocked as the switch to the siding was removed years ago.


The Alleson Mesh Reversible Basketball Jersey is designed with a colorfast polyester for added durability, which will help to keep your jersey bright all year long. The moisture wicking finish helps to keep moisture away from your body while you sweat. Designed with an over sized, pro-cut, wide shoulder design, this jersey allows a wide range of motion that won't hold you back. The reversible layers make this two basketball jerseys in one. With a wide selection of colors to choose from, your sure to find your team colors. The jersey bottom is open for easy decoration. This jersey is priced right, and made with the attention to detail that you deserve.


We're happy to connect with you. Have questions? You can always contact a staff member or send us a message. We'll get back to you as soon as we can!
Two English services, one sermon.
Our office is open Monday through Thursday from 9am to 4pm. Follow the signs to the office, to the right of the main entrance.


text:
Review: Let Me In
By Glenn Morris February 20, 2020
Exactly two years after Let the Right One In was unleashed in Sweden, an American version re-titled Let Me In defies all expectation. It does proper justice to the established work, much in the same way that Sin City did proper justice to Frank Miller graphic novels. That is to say, almost carbon copied for fear of screwing things up the way remakes and adaptations often do. The result is visually stunning, well acted, and a fraction of an improvement while distinctly uneventful to those familiar with the original.
"Improvement!? Blasphemy." That's what die-hard foreign fans will spit my way, and I would agree with them if not for the original being so flawed. Still, Let the Right One In deserved this kind of tuning for the subtitle adverse, but… ok maybe improvement suggests more than I'm willing to grant. For everything that works better, something else is lost in translation, in ways that sometimes result in sillybeans of bloodthirst. The latter is exemplified in decade-old-quality computer generated action and makeup closer to comedy than the more harrowing frames of its predecessor.
Even exchange begins with a scene more firmly rooted in the novel's 80's roots, convenient for Ronald Regan telecasts establishing a word of misappropriated righteousness. This theme is mirrored in the less-than-subtle shift of a main character's mother being blindly of the Bible. She hypocritically ignores her only son Owen (name changed because nobody in America has ever been called Oscar) who is bruised from beatings at school and likes to stab inanimate objects he refers to as "little girl." One of the nice touches in this remake is to keep Owen's mother out of frame or out of focus so that his home life is that much lonelier. His parents are preoccupied with their divorce process, alienating young Owen further.
Throughout the film there's a visual playfulness that enhances some of the iconic moments of the original. Unwoven to LOST composer Michael Giannaccio's music, these allow for a more fluid presentation. My favorite touch by far is the low-tone yellow light used to accent some of the scenes where Owen is coupled with Abby, a vampire girl who can't be judgmental of his androgyny when she herself is barely human. It serves to convey warmth between them, something I rarely felt watching the original.
It's a shame there's still no palpable chemistry between these two actors. See, that's the snag. In the role of Abby, Chloe Grace Moretz is careful in her approach. She wants us to draw our own conclusions as to her nature, just as we did in the original. This may lie at the fault of the direction of Matt Reeves, made more popular for the technical choices of Cloverfield than drawing the best out of actors. What we're looking at here is a girl (yes a girl, as all question of gender has been removed from the novel) who doesn't know what she is, doesn't know what she wants, and is stuck in a state of desperate need and survival instinct. End of sad, slow-crawling story.
That's a problem. Why? Because the girl in the Swedish Let The Right One In was a weak actress. She was a child so nobody expected more, but Moretz in Let Me In actually has the capacity to deliver a true persona. We've seen that in Kick-Ass and (500) Days of Summer. Instead, her finest contribution here is in knowing when to be generous to her co-star, Kodi Smit-McPhee who looks the part but can't seem to run with it.
The movies orbit the twelve year old vampire and similarly aged loner boy meeting just as the bitty bloodsucker's guardian is getting on in years. The old man's life is pitiful, and he's played masterfully this time around by the finally acknowledged Richard Jenkins after the actor's own thankless contributions. This older character is unnamed and like Owen's mother is also kept from closeups in contrast to the original. Heartbreakingly pitiful, he's exactly why the vampire knows she could just as likely ruin her new friend as become his companion.
Let the Right One In portrayed a sterile relationship between the boy and his monster. He is the potential connection to humanity she doesn't want to live without, suitable enough because he isn't pulling the legs off of crabs, and she is his potential first girlfriend, because nobody warm blooded will have him. Replication of this poses a problem when you've cast Hit-Girl, because even at her lowest presentability she's still a Hollywood starlet.
This was where the American remake's opportunity resided. A lively girl (when fed) could have shown interest in an awkward, sensitive boy for better or worse. Vampire desert island scenario. It was left untapped despite marketing for the film being largely focused on the casting of blonde-hair-doe-eyes Chloe Moretz. The movie poster she isn't curled up on features a blood smeared snow angel, but her character, like in the original film, is never desirable except by default.
Had Chloe Moretz been encouraged to play cat and mouse, or rediscover life in her undeath, only to waver in her motives and desires after looking in the eyes of her older companion, we might have had a superior film.
Review: M3GAN
Review: Babylon
Review: Avatar: The Way of Water


This is a placeholder page for Lewis Wasserman, which means this person is not currently on this site. We do suggest using the tools below to find Lewis Wasserman.
You are visiting the placeholder page for Lewis Wasserman. This page is here because someone used our placeholder utility to look for Lewis Wasserman. We created this page automatically in hopes Lewis Wasserman would find it. If you are not Lewis Wasserman, but are an alumni of East Meadow High School, register on this site for free now.